Nucleotrace has developed new technology from the bottom-up to meet key objectives outlined in the FDA Drug Supply Chain Act and FDA Supply Chain Monitoring Toolkit. Transactions recorded on a centralised database or blockchain are only a proxy for physical transactions in the real world. Nucleotrace addresses this insecurity by creating an immutable link between the virtual world of a database and the physical world of a product. Our technology allows all audit trail information, for each ingredient in a product, to be rapidly recovered from the final formulation. The Nucleotrace platform is also designed for seamless integration into existing product serialization systems. In June 2019, Nucleotrace was accepted onto the FDA Emerging Technologies Program.